SHB-04-CD22
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SHB-04-CD22, covering 2026-01-16 to 2026-01-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies [Phase 1, Phase 2]